A monoclonal antibody produced by recombinant DNA technique that specifically binds to B lymphocyte stimulator protein (BLyS), thereby inactivating it.

Therapeutic Effect(s):
↓ survival of B cells, including auroreactive ones and ↓ differentiation into immunoglobulin-producing plasma cells. Result is ↓ disease activity with lessened damage/improvement in mucocutaneous, musculoskeletal and immunologic manifestations of SLE.